Healthcare & Drug Security: Mission Domain Intelligence Guide

A hospital that cannot access its imaging system diverts ambulances. A falsified antimalarial with no active ingredient kills quietly, one patient at a time, and nobody codes it as a security incident.

What Healthcare & Drug Security covers as a mission domain

Healthcare and drug security intelligence covers threats to the delivery of care and to the integrity of the pharmaceutical supply chain. On the delivery side this means ransomware and intrusion against hospitals and health systems, attacks on health facilities and personnel in conflict, medical device and clinical technology exposure, and continuity planning for diversion and downtime. On the product side it means falsified and substandard medicines, diversion and theft of controlled substances, illicit online pharmacies, active ingredient sourcing risk, and the shortage dynamics that create the market gaps counterfeiters fill.

Sub-areas include health sector cyber threat monitoring, physical protection of facilities and staff, pharmaceutical anti-counterfeiting and serialisation analysis, controlled substance diversion investigation, and supply resilience for critical medicines and devices. Actors span ransomware affiliates that deliberately target providers for their low downtime tolerance, organised networks manufacturing and distributing falsified product across borders, insiders diverting controlled stock, and armed groups that strike health facilities as a deliberate tactic.

Why it matters

Health system disruption is measurable in mortality. Studies of ransomware at hospitals show longer waits, diverted ambulances and worse outcomes for time-critical presentations, and the effects spill into neighbouring facilities that absorb the load. Falsified medicines are estimated to make up a substantial share of supply in some low and middle income markets, undermining treatment and accelerating antimicrobial resistance. Attacks on health care in conflict remove services from populations that have no alternative provider.

What analysts actually look for

These are the concrete, observable signals that carry weight in this area of work:

A provider organisation appearing on a ransomware leak site, or ambulance diversion notices and elective cancellations without a stated clinical reason.
Regulatory alerts describing product with correct packaging but failed assay, indicating a sophisticated falsification operation rather than crude copying.
Serialisation and verification failures clustering at one distributor or repackager, which is where diverted and falsified stock usually re-enters legitimate channels.
Online marketplaces and messaging channels offering prescription-only medicines without prescription, priced well below wholesale acquisition cost.
Controlled substance inventory discrepancies concentrated on one shift, one dispensing cabinet or one clinician's override pattern.
National shortage lists lengthening for a molecule with a single active ingredient source, the precondition for counterfeit market entry.
Cold chain excursions or temperature logging gaps on biologics consignments moving through an unfamiliar transhipment route.
Reports of attacks on health facilities, ambulances or health workers clustering geographically ahead of an offensive or displacement wave.

Where the data comes from

Authoritative and openly available collection points. Always confirm licensing and terms before operational or commercial use:

WHO Medical Product Alerts — Global alerts on falsified and substandard medical products with batch numbers, images and affected regions.
FDA Drug Shortages database and MedWatch — Current and resolved shortages, recalls and adverse event reporting for the United States market.
EMA shortages catalogue and EMVO — European shortage listings and the verification system underpinning falsified medicines directive checks.
HHS HC3 — Health sector cyber threat briefs, sector alerts and analyst notes aimed specifically at providers.
Insecurity Insight and WHO Surveillance System for Attacks on Health Care — Documented incidents of attacks on health facilities, staff, patients and transport in conflict settings.
INTERPOL Operation Pangea reporting — Periodic results on illicit online pharmacy takedowns, seizures and network typologies.
CISA advisories and ICS medical device alerts — Vulnerability and threat advisories covering clinical technology and hospital operational systems.
National regulator recall and enforcement registers — Batch-level recalls, import alerts and enforcement actions used to trace product back through distributors.

A working method

A repeatable sequence beats ad-hoc searching. This is a practical starting workflow:

Define the asset at risk — Separate care delivery, clinical technology and pharmaceutical product, because the threat actors, indicators and mitigations differ entirely.
Baseline the sector threat — Track leak sites, sector advisories and incident reporting to establish which actors are currently active against providers in your region.
Map the supply chain — Trace critical molecules and devices to active ingredient source, manufacturing site and distributor layer, identifying single points of failure.
Monitor product integrity — Watch regulator alerts, verification failure rates and grey-market listings, and correlate falsification alerts with concurrent shortages.
Investigate diversion patterns — Analyse dispensing, inventory and override data for concentration by person, location or time rather than treating discrepancies individually.
Assess continuity — Test whether clinical operations can run through extended downtime or product unavailability, and quantify the point where care is degraded.
Report to acting parties — Route product findings to regulators, cyber findings to the provider and sector ISAC, and conflict incident data to protection actors.

How this connects across the intelligence taxonomy

Intelligence work does not respect neat boundaries. The mission domain you are working, the disciplines you practise, and the data points you pivot on are one connected system. These are the direct relationships for this entry — every link is also a tag, so you can follow any thread across the whole library.

Practised with these disciplines

Medical Intelligence — Health Systems, Capability, and Medical Threats
Epidemiological Intelligence — Disease Occurrence, Spread, and Public Health Threats
Criminal Intelligence — Intelligence Supporting Criminal Investigation
Corporate Intelligence — Understanding Companies, Structure, and Control
Legal Intelligence — Law, Litigation, and Regulatory Intelligence
Breach Intelligence — Exposed Credentials and Compromised Data

Worked in these data points

Company / Organization — A legal entity — corporation, LLC, NGO, or business.
Facility / Site — A physical installation — plant, base, port, data centre — with a fixed footprint and function.
Data Breach — A known data breach or leak incident with exposed records.
Person / Name — A named individual — the subject of identity resolution and profiling.
Event / Incident — A discrete real-world occurrence — protest, strike, breach, seizure — with time, place, and actors.
Shipment / Bill of Lading — A consignment record linking shipper, consignee, goods, and route.

Adjacent mission domains

Inside the platform: where Healthcare & Drug Security lives

The Quantus platform is 204 pages behind a 147-item sidebar organised into six working groups: Command (24 items), Dashboards (15), Threat Theaters (14), Intelligence Domains (15), Investigate (34), and Administration (45). This entry is not a page in isolation — it is a thread running through several of them.

The modules that matter most here:

domain.php?d=healthcare — Healthcare & Drug Security dashboard
theater.php?d=healthcare — Threat theater view
search.php — Company / Organization profile
correlate.php — Correlation graph
cases.php — Case management

Each dashboard is local-first: it renders from the platform’s own database rather than depending on a live third-party call, so it still works when an upstream API is unreachable or rate-limited. Heavy aggregates are cached with a hard query time cap and degrade to the last good value instead of hanging the page.

Automation, playbooks and AI skills

Analysis that only happens when someone remembers to run it is not a capability. The platform ships a 30-step automation pipeline (cron.php) that collects, ingests, resolves, enriches, correlates and scores on a schedule — 25 seeders, 11 resolvers and 7 enrichment runners, all idempotent and cursor-based so a run can be interrupted and resumed without duplicating or losing work.

Relevant playbooks

Of the 14 incident playbooks in playbooks.php, these apply directly to Healthcare & Drug Security:

Ransomware Incident Intelligence — a step-checked workflow with the pivots, sources and handling rules already wired in.
Breach & Credential Exposure — a step-checked workflow with the pivots, sources and handling rules already wired in.

AI skills that apply

The 16 one-click operations in ai-skills.php are deterministic jobs, not free-text generation. The ones that matter here:

Threat Hunt
Correlate Infrastructure
Run Alert Rules
Summarise (Copilot)
Generate Report

Alerting closes the loop: rules in alerts.php fire on new indicators matching a saved query, so a first sighting in this area raises a notification rather than waiting to be noticed at the next review.

Feeds, data sources and the API

The collection layer runs a feed registry of free, machine-readable sources — bulk blocklists and trackers (Maltrail, IPsum, FireHOL, the full abuse.ch corpora, phishing databases, Emerging Threats, Spamhaus, DigitalSide, ThreatView), authoritative government feeds (CISA KEV, OFAC, UN and EU sanctions lists), and reference datasets (RIR allocations, ip-to-ASN and geolocation tables, MITRE ATT&CK, EPSS). collect.php pulls them server-side on a schedule; feeds.php and source-catalog.php show what is registered, what it covers and when it last ran.

Anything the platform holds is reachable programmatically. The REST API in api.php exposes 11 endpoints — status, stats, search, lookup, recent, export, bulk_check, top_threats, by_category, categories, check — and export.php streams 18 formats in bounded chunks, so a million-row export neither exhausts memory nor times out:

STIX 2.1, MISP, OpenIOC 1.1, CEF (ArcSight), LEEF 2.0 (QRadar), Zeek/Bro intel, Snort/Suricata rules, Palo Alto EDL, BIND RPZ, hosts blackhole, iptables, CSV, JSON, NDJSON/JSONL, XML.

That covers the CTI standards (STIX 2.1, MISP, OpenIOC), SIEM ingestion (CEF, LEEF, Zeek), detection engines (Snort/Suricata), and direct enforcement (Palo Alto EDL, BIND RPZ, hosts, iptables) — so intelligence developed here can be actioned in the tools you already run, without a manual reformatting step. A TAXII 2.1 server and a MISP/RSS feed are also served for pull-based sharing.

Use cases

Three ways this entry earns its keep in day-to-day work:

Triage under time pressure. An artifact or report lands and you need a defensible read in minutes, not days. Define the asset at risk is the first move; the platform pre-computes the enrichment so the analyst spends the time on judgement rather than lookups.
Building the picture. A single indicator is rarely the story. Map the supply chain turns one artifact into a network — shared infrastructure, repeated selectors, the same operator behind different names — via the correlation graph and the cross-entity link engine.
Producing something actionable. Analysis that ends in a document nobody can use is wasted. Report to acting parties feeds the case file, the detection rule, the block list or the referral — with sourcing attached so the recipient can verify it.

Case management (cases.php), watchlists, saved searches and scheduled reports mean the work persists between sessions and survives an analyst leaving the team.

How each sector uses Healthcare & Drug Security

The same entry is worked very differently depending on who you are, what authority you hold, and what you are ultimately producing. A military analyst is supporting a commander’s decision; a journalist is meeting a publication standard; an NGO caseworker is protecting a person. The underlying artifacts are shared — the constraints, outputs and thresholds are not.

🎖 Military and defence

Defence medical and force protection staff use this domain for deployed medical supply integrity, continuity of host nation health services that military operations depend on, and protection of medical facilities and personnel under international humanitarian law. Falsified medicines in a deployed supply chain are a direct force health risk, and cyber disruption of a partner nation health system affects casualty evacuation planning. Products feed medical logistics assurance, force health protection and civil-military coordination. The constraint is absolute on the protective side: medical facilities, transports and personnel are protected objects, and analysis exists to safeguard them and to document violations, never for any other purpose.

🕵 National intelligence

National intelligence interest covers ransomware and state-aligned intrusion against health systems as critical national infrastructure, pharmaceutical supply chain dependency on a small number of active ingredient producers, and organised networks manufacturing falsified medical products at scale. Fusion combines open incident and recall data, sector threat reporting, trade data and liaison material. Because health providers are frequently under-resourced, the highest-value output is often a shareable warning to the sector rather than a classified assessment. Judgments should quantify continuity consequence, since the decision-relevant question is what happens to patients when a system goes down.

👮 Law enforcement

Law enforcement work covers falsified medicine manufacture and distribution, controlled substance diversion, illicit online pharmacies, and intrusion into provider networks. Evidence is a blend of laboratory analysis of seized product, supply chain documentation, prescription and dispensing records, and digital forensics, each with its own custody requirements. Legal process runs to production orders on platforms and payment providers, mutual legal assistance for manufacturing jurisdictions, and regulated access to patient-adjacent records. Charging typically rests on fraud, trademark, medicines regulation and computer misuse offences, and cases usually turn on linking a physical product to a distribution route and a beneficiary.

🔍 Private investigation and corporate security

Corporate security in pharmaceutical, device and provider organisations uses this for brand protection, supply chain integrity, insider risk and third-party assurance. Work includes test purchasing from suspect online sellers under legal advice, tracing distribution routes for diverted product, screening distributors and wholesalers, and assessing continuity exposure to single-source suppliers. Private actors must not access patient records, must handle any incidentally obtained health information under strict legal constraint, and must not conduct covert surveillance of clinicians or patients. Findings on criminal manufacture belong with regulators and police, supported by properly documented evidence.

📰 Journalism and OSINT media

Reporting in this domain touches patient safety directly, so verification standards must be high. Falsification claims need laboratory evidence or a regulator alert rather than packaging appearance alone, and ransomware attribution needs more than a leak site listing, which is frequently exaggerated or recycled. Patient data appearing in leaks must never be published or described in identifying detail, regardless of news value. Sources inside hospitals face dismissal and licensure consequences. Give providers and manufacturers a genuine right of reply, and consider whether publishing details of a live incident increases patient risk during recovery.

🌍 NGO, humanitarian and human rights

Health NGOs and human rights organisations work this domain through access to essential medicines, documentation of attacks on health care, and the consequences of shortage and falsification in low-resource settings. Practice is patient centred and confidentiality-absolute: patient information never leaves the clinical context. Do-no-harm includes weighing whether publicising a falsified product will deter people from seeking legitimate treatment. Documentation of attacks on health facilities, personnel and transport should be preserved to standards that support accountability mechanisms. Duty of care covers staff working in facilities that are themselves targets, including psychological support after mass casualty events.

🎓 University and research

Research spans health system resilience, pharmaceutical supply chain economics, medical device security and falsification prevalence, and the recurring methodological problem is denominator uncertainty: prevalence estimates for falsified medicines rest on convenience samples that cannot be generalised. State sampling frames explicitly and avoid extrapolating national figures from seizure data. Ethics approval is mandatory for any patient-adjacent work, and device security research requires coordinated disclosure arrangements agreed before testing. Publish protocols and analytical code, cite regulator alert identifiers precisely, and observe embargoes agreed with manufacturers during remediation.

Playbook: working Healthcare & Drug Security end to end

A repeatable sequence, from the moment the requirement lands to the moment a product is delivered and the case is closed out. Each phase states what you are trying to establish, not merely what to click — the point is a defensible chain of reasoning, not a checklist.

Phase 1 — Scope the estate or the product line

Decide whether the task is provider-side continuity, product-side integrity, or both, and enumerate what is in scope: facilities, clinical systems and connected devices, or products, presentations, markets and distribution channels. Health organisations routinely underestimate their own estate, particularly connected devices and third-party managed systems. A good output is a scoped inventory with owners named for each component. Stop when every clinical service traces to the systems and suppliers it depends on.

Phase 2 — Baseline the threat picture for the sector

Assemble known threat activity against health providers and pharmaceutical supply chains: ransomware groups with a demonstrated pattern of targeting the sector, intrusion techniques observed, device and software vulnerability families, and the falsification typologies affecting your products. Use sector information sharing bodies rather than generic threat feeds, since health-specific tradecraft differs. A good output is a threat profile mapped to a recognised technique framework. Stop when each threat has an identified relevance judgment for the scoped estate.

Phase 3 — Map clinical consequence, not just system criticality

For each system, establish what happens clinically when it is unavailable: imaging unavailable means diversion of stroke and trauma patients, pharmacy systems down means manual dispensing and error risk, electronic records down means unknown allergies. This translation is what turns a technical risk register into something a clinical director will act on. A good output is a consequence table expressed in clinical terms with tolerable downtime for each service. Stop when every critical system has a stated clinical downtime tolerance.

Phase 4 — Assess technical exposure defensively

Review architecture and process rather than probing: network segmentation between clinical and corporate estates, remote access and vendor connections, device inventory completeness and patch pathways, backup isolation and tested restoration, and monitoring coverage in clinical networks. Medical devices frequently cannot be patched on normal cycles, so compensating controls matter more than patch status. A good output is a gap assessment mapped to a recognised control framework. Stop before any scanning or testing without written authorisation from the system owner.

Phase 5 — Monitor product integrity signals

Track regulator alerts, recall notices, field safety notices, batch-level complaints, and reports of therapeutic failure that may indicate substandard or falsified product in circulation. Correlate with shortage data, because the market gap created by a shortage is where falsified product enters. A good output is a watchlist of products with shortage exposure and any linked integrity signals. Stop when each alert has an assessed relevance to your markets and distribution channels.

Phase 6 — Investigate distribution and diversion

For suspected falsification or diversion, work the route: authorised distributor records, parallel trade documentation, serialisation and verification data where implemented, online seller infrastructure, and payment and shipping patterns. Test purchasing may be lawful but requires legal advice and careful documentation. Diversion of controlled substances usually shows in dispensing anomalies and inventory reconciliation rather than externally. A good output is a documented route with the point of entry into the legitimate chain identified. Stop at the evidential boundary and refer to the regulator or police.

Phase 7 — Prepare and exercise continuity

Test the downtime procedures that actually matter: paper prescribing and dispensing, manual laboratory result flows, diversion agreements with neighbouring providers, communication when the phone system depends on the same network, and clinical prioritisation when systems are unavailable for days rather than hours. Exercises should include clinical staff, not only technical teams. A good output is an exercised continuity plan with observed failure points documented. Stop when the plan has survived a realistic exercise rather than a tabletop walk-through.

Phase 8 — Run coordinated disclosure properly

Where a vulnerability is identified in a device, clinical system or provider-facing service, follow coordinated disclosure: notify the manufacturer or operator through a published channel, involve the national CERT and the relevant health regulator, agree a remediation timeline, and withhold technical detail until patients are protected. Health device disclosure timelines are frequently longer than in other sectors because of clinical safety recertification. A good output is a documented disclosure record with agreed timelines. Stop before publishing anything that could be used against a live clinical system.

Phase 9 — Document attacks on health care for accountability

In conflict settings, record incidents affecting facilities, personnel, transport and patients with date, location, actor where identifiable, damage and clinical consequence, preserving imagery and testimony to evidentiary standards. These records support accountability mechanisms and humanitarian advocacy. Consent and confidentiality for patients and staff are non-negotiable. A good output is a structured incident record suitable for submission to an accountability mechanism. Stop collecting whenever a witness signals risk or distress.

Phase 10 — Report to clinical and executive audiences

Produce two renderings from one assessment: a clinical and executive product expressed in patient impact, downtime tolerance and mitigation cost, and a technical product for security and engineering teams. Health leadership does not act on vulnerability counts but does act on diversion hours and cancelled procedures. A good output is a board-level product with a clear ask and a technical annex. Stop when the executive version could be acted on without the technical annex present.

The platform ships this as a step-checked workflow in playbooks.php, so progress is recorded against a case rather than held in someone’s head.

Source register: what to collect from, and how

Sources are listed with their access model so you can plan around cost and licensing before you build a dependency on them. Open means no account required; registration means a free account or API key; licensed means paid or institutional access. Always confirm current terms — licensing changes, and a source that was free for research may not be free for commercial or evidential use.

Source	Access	What it gives you	How it is used here
WHO medical product alerts and surveillance system	Open	Global alerts on falsified and substandard medical products with batch details, imagery and affected regions.	Authoritative confirmation that a specific product and batch has been identified as falsified or substandard.
US FDA drug shortages and safety reporting	Open	Current and resolved drug shortage listings with reasons, plus adverse event and recall reporting systems.	Identifies market gaps that falsified product exploits and tracks recalls affecting supply continuity.
European Medicines Agency shortages and safety information	Open	European shortage catalogue, referral procedures, safety communications and regulatory actions on medicinal products.	European counterpart shortage and safety picture, essential where supply chains differ by region.
US HHS Health Sector Cybersecurity Coordination Center	Open	Sector-specific threat briefs, analyst notes and alerts covering ransomware and intrusion activity against health organisations.	The most health-specific open threat reporting available, mapping actor behaviour to provider environments.
CISA advisories including medical device alerts	Open	Advisories on vulnerabilities in medical devices and clinical systems, plus general critical infrastructure threat guidance.	Primary feed for device and clinical system vulnerability relevance assessment against the estate.
ENISA health sector threat reporting	Open	European analysis of threats to the health sector including incident trends and regulatory context under NIS2.	European threat framing plus the regulatory expectations providers are assessed against under sector security obligations.
INTERPOL pharmaceutical crime reporting	Open	Reporting on international operations against illicit medicine manufacture and distribution, including typologies and seizure outcomes.	Establishes network typologies, manufacturing hubs and known distribution routes for falsified medical products across borders.
Insecurity Insight and attacks on health care documentation	Open	Incident-level records of violence against health workers, facilities, transport and patients in conflict-affected settings.	The evidence base for documenting and analysing attacks on health care for accountability work.
National regulator recall and enforcement registers	Open	Country-level recall notices, enforcement actions, licence suspensions and import alerts for medicines and devices.	Confirms regulatory action in specific markets and identifies distributors subject to enforcement.
MITRE ATT&CK	Open	Structured knowledge base of adversary tactics and techniques observed in real intrusions, with mitigations and detections.	Common language for mapping observed health sector intrusion behaviour to detection and control gaps.
National Vulnerability Database	Open	Catalogue of publicly disclosed vulnerabilities with severity scoring, affected product identifiers and references.	Relevance assessment for clinical system and device vulnerabilities against the asset inventory.
Health-ISAC and sector information sharing bodies	Registration	Member-based sharing of threat indicators, incident experience and mitigations specific to health organisations.	Peer sharing of active threat activity that is not published openly, with sector-relevant context.
WHO Model Lists and essential medicines documentation	Open	Reference lists of essential medicines and supporting guidance on selection, supply and quality assurance.	Defines which products matter most for continuity and prioritisation in shortage and falsification response.
Peer-reviewed literature on falsification prevalence and health system resilience	Open	Published studies on substandard and falsified medical product prevalence, sampling methods and health system impact.	Provides methodological benchmarks and prevents extrapolation from seizure data to population prevalence.

Prefer sources that publish a methodology and a revision history. A dataset that changes silently is a liability in any product that has to survive challenge.

Tooling

Tools commonly used against Healthcare & Drug Security. None of these replace judgement, and each carries its own failure modes — know what a tool infers versus what it observes.

Asset and device inventory platforms — Discovers connected clinical devices and systems passively. Passive discovery is safer clinically but produces incomplete inventories that need reconciliation.
MISP or OpenCTI — Structured sharing of health sector threat indicators with peers and CERTs. Value depends on the sharing community rather than the platform.
Serialisation and verification systems — Checks pack-level identifiers against manufacturer records at dispensing. Only effective where the market has implemented serialisation end to end.
Laboratory analysis and field screening devices — Confirms active ingredient presence and quantity in suspect product. Field screening indicates, laboratory analysis proves, and only the latter supports prosecution.
Hunchly — Preserves illicit online pharmacy pages with hashes and timestamps before takedown. Captures rendered pages, so infrastructure data needs separate collection.
Passive DNS and certificate transparency search — Pivots between illicit pharmacy domains and shared infrastructure. Infrastructure reuse is common, but so are shared hosting false positives.
Tabletop and simulation exercise frameworks — Tests clinical downtime procedures with real staff. Only useful when clinicians participate rather than technical teams alone.
Risk registers expressed in clinical impact terms — Translates technical exposure into diverted patients and cancelled procedures. Requires clinical input to populate honestly.

AI skills and automation in detail

These are deterministic jobs with defined inputs and outputs, not open-ended prompting. Each is idempotent and cursor-based: interrupt one and it resumes where it stopped rather than duplicating work or losing progress.

Threat Hunt — Runs saved hypotheses against the corpus and surfaces what matches, with the query preserved as a versioned artifact.
Correlate Infrastructure — Builds the cross-entity link graph: shared hosting, reused certificates, overlapping registrants, repeated selectors.
Run Alert Rules — Evaluates saved rules against new data so a first sighting raises a notification rather than waiting for review.
Summarise (Copilot) — Produces a narrative summary beside the underlying records. It explains; it never creates indicators or assigns attribution.
Generate Report — Assembles a sourced product from the current case or query, with provenance attached to each element.

A note on the boundary: the only skill that involves a language model is Summarise (Copilot), and it writes prose about records that already exist. Nothing else on this list involves generation of any kind. No indicator, relationship or attribution in the platform originates from a model. See the full skill list.

Tradecraft notes

The distinctions that separate a competent analyst from a fast one:

Express every technical risk in clinical consequence. A board will not act on an unpatched system count but will act on the statement that imaging loss diverts stroke patients to a hospital forty minutes away.
Falsified product enters through the gap a shortage creates. Correlate shortage listings with falsification alerts, because the market signal reliably precedes the criminal supply by weeks to months.
Packaging appearance is not evidence of falsification. Sophisticated counterfeits are visually perfect and legitimate product varies by market, so laboratory analysis or a regulator alert is the standard before any public claim.
Medical devices frequently cannot be patched on normal cycles because of clinical safety recertification, so assess compensating controls and network isolation rather than treating patch status as the measure.
Ransomware leak site listings are marketing, frequently exaggerated, sometimes recycled and occasionally fabricated. Verify with the provider or the regulator before reporting a health data breach as fact.
Never handle patient-identifiable data outside a lawful clinical or regulated context, including data appearing in leaks. There is no analytic value that justifies it and the legal exposure is severe.
Test continuity with clinicians, not with technical teams. Paper processes that look workable in a plan fail immediately when a busy department tries to use them for three days without electronic records.

Measuring whether it is working

Capability claims should be falsifiable. These are the measures that show whether work on Healthcare & Drug Security is producing anything, and they are worth baselining before you change process or tooling.

Proportion of critical clinical systems carrying a documented downtime tolerance agreed with the clinical service that depends on it.
Time from a device or clinical system advisory to a completed relevance assessment against the asset inventory.
Number of vulnerabilities remediated through coordinated disclosure with agreed timelines and no public exposure of live systems.
Restoration time achieved in exercises measured against the clinically tolerable downtime agreed for each affected clinical service.
Share of falsification alerts assessed for relevance to the organisation's markets and distribution channels within a defined window.
Rate at which shortage listings for critical products are matched to a mitigation or substitution plan.
Number of attacks on health care documented to an evidentiary standard suitable for submission to accountability mechanisms.

Beware of measuring volume alone. Indicator counts and report counts rise easily and say little; time-to-attribution, proportion of findings that survive review, and how often a product changed a decision say a great deal.

Common pitfalls

Hospitals under-report incidents because of regulatory, reputational and litigation exposure, so open incident counts understate the real rate substantially.
Substandard and falsified are distinct: one is a manufacturing quality failure, the other is deliberate deception, and remedies differ.
Shortage causes are usually mundane, involving manufacturing quality holds and thin margins, not sabotage or hoarding.
Serialisation verification failures are dominated by legitimate scanning and data errors, so a raw failure count is not a counterfeit count.
Attributing patient harm to a cyber incident requires clinical evidence, and premature claims undermine otherwise sound reporting.
Attacks on health care are frequently reported by parties to a conflict with strong incentives to exaggerate or deny.

Legal and ethical considerations

Patient data is protected under HIPAA, GDPR and equivalent regimes, and even incident metadata can identify individuals in small facilities, so work at the organisational level and never handle clinical records. Attacks on health care may constitute violations of international humanitarian law, which raises the evidentiary bar for any published claim. Vulnerability findings in medical devices must go through coordinated disclosure with the manufacturer and regulator. Naming a product as falsified without regulator confirmation carries serious liability.

Data integrity: no fabrication, no drift, no hallucination

Intelligence that cannot be traced back to a source is not intelligence, it is assertion. Everything in this entry — and everything in the platform behind it — is built on a small number of non-negotiable rules.

Provenance on every record

Every indicator carries the source that supplied it, a first-seen and last-seen timestamp, and a sighting count. Where several feeds report the same artifact, each contribution is recorded separately rather than collapsed, so you can see whether a finding rests on one source or twelve. Source attribution travels with the data into every export, so a recipient can audit a claim without asking you for the working.

Nothing is invented to fill a gap

If the platform has no data for Healthcare & Drug Security, it says so. Empty is displayed as empty — never padded with plausible-looking placeholder values, sample records or illustrative examples that a reader might mistake for observations. A dashboard with no rows is a true statement about collection coverage, and it is treated as a gap to close, not a blemish to hide.

Scoring is deterministic and reproducible

Threat scores, reputation grades and risk tiers are computed from stated inputs with fixed weights, not estimated. The same inputs always produce the same output, and the formula is visible rather than a black box. Aggregates are cached with an explicit time-to-live so a figure on screen is never silently stale — and when a heavy query exceeds its time budget the platform serves the last known-good value and labels it, rather than inventing a fresh number or hanging.

Where AI is used, and where it is not

Language models summarise and explain. They do not create indicators, assign attribution or manufacture relationships. No IP address, wallet, hash or identity in the platform originates from a model — every one is ingested from a named feed, resolved from a reference dataset, or entered by an analyst with a source recorded. Copilot output is presented as narrative alongside the underlying records, never in place of them, so a reader can always check the summary against the evidence.

Guarding against drift

Enrichment is additive and timestamped rather than overwriting. Reference data — sanctions lists, allocations, taxonomies — is re-synchronised from the authority on a schedule instead of being edited in place, so local copies cannot quietly diverge from the source of truth. Attribution is recorded with a confidence level and the reporting it rests on, and inferred relationships are labelled as inferred. When a source retracts or corrects, the correction propagates rather than leaving a stale assertion behind.

What this means for you

You can put a finding from this platform in front of a regulator, a court, a board or a partner agency and show where each element came from. That is the standard the tooling is built to — because in this work, being confidently wrong is more damaging than being usefully uncertain.

By the numbers

The taxonomy this entry belongs to is not a marketing list — it is the actual structure of the platform: 52 mission domains, 52 intelligence disciplines and 65 data points, each with a live dashboard behind it. Supporting that: 18 indicator types, 14 playbooks, 16 AI skills, 18 export formats and a 30-step automated pipeline.

This particular entry connects directly to 6 intelligence disciplines, 6 data points, 5 closely related entries — every one of them a tag you can follow, and a dashboard you can open.

Questions analysts actually ask

Why are health providers targeted so consistently by ransomware?

Because their tolerance for downtime is extremely low and their security investment historically lags other critical sectors. Care cannot be paused: when systems fail, ambulances divert, procedures are cancelled and patients come to harm, which creates enormous pressure to restore quickly. Estates are also large, heterogeneous and full of connected devices that cannot be patched on normal cycles, with flat networks and extensive third-party access. The combination of high consequence and broad attack surface makes providers attractive to financially motivated actors. Mitigation is mostly architectural and procedural rather than exotic: segmentation, isolated tested backups, and exercised clinical downtime procedures.

How do I tell a falsified medicine from a substandard one?

Falsified means deliberately misrepresented identity, composition or source, which is a crime. Substandard means an authorised product that fails to meet quality specifications, which is usually a manufacturing or storage failure. The distinction determines the response: falsification requires criminal investigation and supply chain tracing, while substandard product requires regulatory action against a known manufacturer and often a recall. Distinguishing them requires laboratory analysis of active ingredient identity and quantity plus verification against the named manufacturer's records. Never assert falsification from packaging appearance alone, since legitimate presentations vary by market and good counterfeits are visually indistinguishable.

What is the link between shortages and falsification?

Direct and predictable. When an essential medicine becomes scarce, prices rise, patients and providers look outside normal channels, and unfamiliar suppliers appear offering stock. That is precisely the environment falsified product is manufactured for. The operational implication is that shortage listings are a leading indicator for falsification risk, and organisations should treat a shortage announcement as a trigger to tighten procurement verification, brief clinicians about unauthorised sourcing, and watch for offers from unfamiliar wholesalers. Monitoring both regulator shortage catalogues and falsification alerts together gives weeks of useful lead time.

Can we test online pharmacies by making purchases?

Sometimes, and only with legal advice. Test purchasing can be lawful for regulators, manufacturers and their agents in some jurisdictions and unlawful in others, and it may involve importing unlicensed medicines, which is separately regulated. Where it is permitted, documentation must be rigorous: ordering records, payment trail, unopened receipt with photographs, and controlled chain of custody to an accredited laboratory. Uncontrolled purchasing destroys evidential value and can expose the purchaser to criminal liability. The safer default for most organisations is documenting the seller's infrastructure and advertising, then referring to the regulator.

What should never appear in a health security product?

Patient-identifiable information, in any form and from any source, including data that has appeared in a public leak. That includes names, record numbers, dates of birth combined with location, images containing identifiers, and clinical detail specific enough to identify an individual in a small community. It also includes live exploitable technical detail about a specific clinical system while patients depend on it. Where a finding requires such material to be understood, it belongs in a restricted channel to the provider, regulator and CERT, not in an analytic or public product.

How long should a medical device disclosure timeline be?

Longer than in most sectors, and agreed rather than imposed. Device remediation frequently requires clinical safety assessment, regulatory notification and sometimes recertification before a patch can be deployed, and a rushed fix can create patient risk greater than the vulnerability. The professional approach is to notify the manufacturer and the relevant health regulator and CERT together, agree a timeline that reflects the clinical constraints, publish compensating controls that operators can apply immediately, and hold technical detail until deployment is realistic. Document the agreed timeline so accountability exists on both sides.

Standards, frameworks and further reading

Work that references a recognised framework is easier to defend, easier to hand over, and easier for a partner to consume:

WHO member state mechanism on substandard and falsified medical products, which defines the terminology and reporting framework.
EU Falsified Medicines Directive and equivalent serialisation regimes, which mandate pack-level verification at dispensing.
NIS2 Directive and national critical infrastructure regimes, which impose security and incident reporting duties on health providers.
IEC 80001 and FDA premarket and postmarket cybersecurity guidance for medical devices, which govern device security risk management.
ISO 27001 and the NIST Cybersecurity Framework, which provide the control framing used in provider gap assessments.
Coordinated vulnerability disclosure under ISO 29147 and ISO 30111, adapted for clinical safety recertification timelines.
Geneva Conventions and Additional Protocols protecting medical facilities, personnel and transports, which underpin attack documentation.
Data protection regimes governing health data, including GDPR special category provisions and equivalent national health privacy law.

References

Primary sources and authoritative references for this entry. Publishers revise and retire material, so treat the retrieval date as part of the citation and re-check before relying on any of it in a formal product.

Medical Product Alerts — World Health Organization. Global alerts on falsified and substandard medical products
Drug shortages and safety reporting — US Food and Drug Administration. Shortage listings, recalls and adverse event reporting
Shortages catalogue and safety communications — European Medicines Agency. European medicine shortage and regulatory safety information
Health Sector Cybersecurity Coordination Center reporting — US Department of Health and Human Services. Sector-specific threat briefs and analyst notes for health organisations
Medical device and control system advisories — US Cybersecurity and Infrastructure Security Agency. Vulnerability advisories affecting medical devices and clinical systems
Pharmaceutical crime operations reporting — INTERPOL. International operations against illicit medicine manufacture and distribution
Attacks on health care documentation — Insecurity Insight. Incident records of violence against health workers, facilities and transport
ATT&CK knowledge base — MITRE. Structured catalogue of adversary tactics and techniques for detection mapping
National Vulnerability Database — US National Institute of Standards and Technology. Catalogue of disclosed vulnerabilities with severity scoring and product identifiers

Link integrity: every reference above was verified with a live request when this page was generated. Where a publisher had moved or withdrawn a document, the link was repointed at a preserved copy in the Internet Archive and marked as archived. Anything with no reachable copy anywhere had its link removed rather than left to rot — the source is still credited, it simply cannot be linked.

Put it into practice

The Quantus Intel threat intelligence platform operationalises this entry: sector threat tracking, falsification and shortage correlation, and diversion pattern analysis mapped to continuity impact. Explore the platform, or browse the rest of the library by following any tag above.